文献速递胸部肿瘤支持与姑息治疗

超越类固醇:类固醇难治性或抵抗性免疫相关不良事件中的免疫抑制剂

Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.
PubMed 文献 · J Thorac Oncol · 2021-07-12

该研究在纪念斯隆凯特琳癌症中心回顾了2011至2020年间接受免疫检查点阻断治疗的2750例肺癌患者,其中51例(2%)因严重irAE接受了类固醇联合其他免疫抑制剂治疗。最常见事件为结肠炎(53%)、肺炎(20%)、肝炎(12%)和神经肌肉毒性(10%)。开始额外免疫抑制剂后90天,57%改善、18%无变化、25%死亡;肝炎和结肠炎改善率较高,神经肌肉毒性和肺炎改善率较低。

要点

  • 类固醇难治性或抵抗性irAE罕见,2750例肺癌患者中仅2%需加用免疫抑制剂。
  • 加用免疫抑制剂后90天,57%改善、18%无变化、25%死亡。
  • 肝炎和结肠炎改善较常见,神经肌肉毒性和肺炎改善较少。

核心结论

  • 类固醇难治性或抵抗性irAE罕见,现有免疫抑制剂对肝炎和结肠炎有帮助,但许多其他irAE仍难治或出现免疫抑制毒性。

研究设计与样本

  • 回顾性研究,纳入2011至2020年纪念斯隆凯特琳癌症中心接受免疫检查点阻断治疗的2750例肺癌患者,其中51例(2%)因严重irAE接受类固醇联合额外免疫抑制剂。

主要发现

  • 额外免疫抑制剂以肿瘤坏死因子-α抑制剂(73%)和霉酚酸酯(20%)为主。
  • 最常见irAE为结肠炎(53%)、肺炎(20%)、肝炎(12%)和神经肌肉毒性(10%)。
  • 开始额外免疫抑制剂后90天,57%改善、18%无变化、25%死亡。
  • 肝炎改善5/6例,结肠炎改善18/27例,神经肌肉毒性改善1/5例,肺炎改善3/10例。
  • 13例死亡中8例直接归因于irAE,4例与免疫抑制毒性相关(3例感染相关死亡,1例药物性肝损伤导致急性肝衰竭)。

临床怎么用

  • 对于类固醇难治性或抵抗性irAE,可考虑加用肿瘤坏死因子-α抑制剂或霉酚酸酯等免疫抑制剂,但需警惕免疫抑制相关毒性。
  • 肝炎和结肠炎患者加用免疫抑制剂后改善可能性较高,神经肌肉毒性和肺炎患者改善可能性较低。

局限性

  • 回顾性研究,样本量小(51例),仅纳入肺癌患者,结论推广需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The optimal management for immune-related adverse events (irAEs) in patients who do not respond or become intolerant to steroids is unclear. Guidelines suggest additional immunosuppressants on the basis of case reports and expert opinion. METHODS: We evaluated patients with lung cancers at Memorial Sloan Kettering Cancer Center treated with immune checkpoint blockade from 2011 to 2020. Pharmacy records were queried to identify patients who received systemic steroids and an additional immunosuppressant (e.g., tumor necrosis factor-α inhibitor, mycophenolate mofetil). Patient records were manually reviewed to evaluate baseline characteristics, management, and outcomes. RESULTS: Among 2750 patients with lung cancers treated with immune checkpoint blockade, 51 (2%) received both steroids and an additional immunosuppressant for a severe irAE (tumor necrosis factor-α inhibitor (73%), mycophenolate mofetil (20%)). The most common events were colitis (53%), pneumonitis (20%), hepatitis (12%), and neuromuscular (10%). At 90 days after the start of an additional immunosuppressant, 57% were improved from their irAE, 18% were unchanged, and 25% were deceased. Improvement was more common in hepatitis (five of six) and colitis (18 of 27) but less common in neuromuscular (one of five) and pneumonitis (3 of 10). Of the patients who died, 8 of 13 were attributable directly to the irAE and 4 of 13 were related to toxicity from immunosuppression (three infection-related deaths, one drug-induced liver injury leading to acute liver failure). CONCLUSIONS: Steroid-refractory or resistant irAEs events are rare. Although existing treatments help patients with hepatitis and colitis, many patients with other irAEs remain refractory or experience toxicities from immunosuppression. A more precise understanding of the pathophysiology of specific irAEs is needed to guide biologically-informed treatments for severe irAEs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Luo J, Beattie JA, Fuentes P, et al. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. J Thorac Oncol. 2021. PMID: 34265432. doi:10.1016/j.jtho.2021.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。